Actinium Pharmaceuticals, Inc. Closes Public Offering Of Common Shares

Published: Jun 30, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE MKT:ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the closing of its previously announced public offering of 1,670,000 shares of its common stock at a price to the public of $7.50 per share. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 250,500 shares of common stock solely to cover over-allotments, if any.

Help employers find you! Check out all the jobs and post your resume.

Back to news